CN103402527B - 用于细胞移植的组合物和方法 - Google Patents

用于细胞移植的组合物和方法 Download PDF

Info

Publication number
CN103402527B
CN103402527B CN201280011169.6A CN201280011169A CN103402527B CN 103402527 B CN103402527 B CN 103402527B CN 201280011169 A CN201280011169 A CN 201280011169A CN 103402527 B CN103402527 B CN 103402527B
Authority
CN
China
Prior art keywords
cell
antithrombase
activator
heparin
thrombin inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280011169.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN103402527A (zh
Inventor
沙维尔·斯特普亨内
艾蒂安·索卡尔
穆斯塔法·纳吉米
斯特凡·埃克胡德特
锡德里克·赫尔曼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Catholique de Louvain UCL
Original Assignee
Universite Catholique de Louvain UCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Catholique de Louvain UCL filed Critical Universite Catholique de Louvain UCL
Publication of CN103402527A publication Critical patent/CN103402527A/zh
Application granted granted Critical
Publication of CN103402527B publication Critical patent/CN103402527B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201280011169.6A 2011-01-25 2012-01-25 用于细胞移植的组合物和方法 Expired - Fee Related CN103402527B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11152119 2011-01-25
EP11152119.1 2011-01-25
PCT/EP2012/051157 WO2012101181A1 (en) 2011-01-25 2012-01-25 Compositions and methods for cell transplantation

Publications (2)

Publication Number Publication Date
CN103402527A CN103402527A (zh) 2013-11-20
CN103402527B true CN103402527B (zh) 2016-04-20

Family

ID=45607724

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280011169.6A Expired - Fee Related CN103402527B (zh) 2011-01-25 2012-01-25 用于细胞移植的组合物和方法

Country Status (12)

Country Link
US (3) US20130302291A1 (enExample)
EP (1) EP2667878B1 (enExample)
JP (1) JP6012629B2 (enExample)
CN (1) CN103402527B (enExample)
CA (1) CA2825252C (enExample)
DK (1) DK2667878T3 (enExample)
ES (1) ES2573522T3 (enExample)
IL (1) IL227529A0 (enExample)
PL (1) PL2667878T3 (enExample)
PT (1) PT2667878E (enExample)
SG (1) SG192124A1 (enExample)
WO (1) WO2012101181A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2667878B1 (en) 2011-01-25 2016-03-30 Université Catholique de Louvain Compositions and methods for cell transplantation
US9775890B2 (en) 2012-01-25 2017-10-03 Université Catholique de Louvain Factor Xa inhibitor used with liver-derived progenitor cells
EP2943206A4 (en) * 2013-01-12 2017-01-04 Cesca Therapeutics Inc. Rapid infusion of autologous bone marrow derived stem cells
MX376437B (es) * 2013-03-15 2025-03-04 Miromatrix Medical Inc Uso de hígado descelularizado por perfusión para recelularización de células de islote.
EP3016665B1 (en) 2013-07-05 2019-09-18 Université Catholique de Louvain Conditioned medium from human adult liver stem cells and its use in the treatment of liver disorders
BR102013033827B1 (pt) * 2013-12-27 2021-09-08 Regenera - Medicina Veterinária Avançada Ltda. Concentrado multipotente e imunocompatível de células-tronco e biofármaco e forma de dosagem que o compreendem
CN108367023B (zh) * 2015-06-11 2021-04-20 马斯特里赫特大学 预防宿主中移植物衰竭的方法
CN106995796A (zh) * 2016-01-26 2017-08-01 李建业 基于细胞因子的细胞处理方法、试剂盒及冻干粉
CN116590227A (zh) 2017-03-03 2023-08-15 日本乐敦制药株式会社 间充质干细胞和肝疾病治疗剂
TW201902467A (zh) * 2017-06-12 2019-01-16 北卡羅來納大學教堂山 用於細胞植入的補釘移植物組成物
JP7264589B2 (ja) * 2017-12-25 2023-04-25 株式会社 資生堂 トロンビンの抑制作用を指標とした皮膚状態改善剤のスクリーニング方法、及びトロンビン作用阻害剤を含む皮膚状態改善剤
WO2019241499A1 (en) 2018-06-13 2019-12-19 Miromatrix Medical Inc. Fistula filler and deployment system
CN113677790B (zh) * 2019-03-26 2024-05-24 普罗米瑟拉疗法公司 用于治疗慢加急性肝衰竭的成体肝祖细胞
CN112608890B (zh) * 2020-12-17 2024-08-20 山东佰鸿干细胞生物技术有限公司 一种防止间充质干细胞粘连的培养方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101151030A (zh) * 2005-03-29 2008-03-26 贝林格尔·英格海姆国际有限公司 用于治疗血栓的包括至少一种直接凝血酶抑制剂的组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9010552D0 (en) 1990-05-10 1990-07-04 Erba Carlo Spa Method for the recombinant production of hirudins and novel hirudins
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5811094A (en) 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5827740A (en) 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
GB0014136D0 (en) 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
DE10202982A1 (de) 2002-01-26 2003-07-31 Augustinus Bader Verfahren und Vorrichtung zum Einbringen von lebenden Zellen in eine biologische Körperflüssigkeit
WO2006126219A1 (en) 2005-05-26 2006-11-30 Fresenius Medical Care Deutschland G.M.B.H. Liver progenitor cells
AU2006292203A1 (en) 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
ATE498005T1 (de) 2005-12-21 2011-02-15 Univ Catholique Louvain Isolierte leberstammzellen
EP2667878B1 (en) 2011-01-25 2016-03-30 Université Catholique de Louvain Compositions and methods for cell transplantation
US9775890B2 (en) 2012-01-25 2017-10-03 Université Catholique de Louvain Factor Xa inhibitor used with liver-derived progenitor cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101151030A (zh) * 2005-03-29 2008-03-26 贝林格尔·英格海姆国际有限公司 用于治疗血栓的包括至少一种直接凝血酶抑制剂的组合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model;Biemond BJ 等;《Thromb Haemost》;19940930;第72卷(第3期);377-380 *
Thrombotic complications after haematopoietic stem cell transplantation: early and late effects;Dimitrios A. Tsakiris 等;《Best Practice & Research Clinical Haematology》;20091231;第22卷;137-145 *
小剂量肝素预防异基因造血干细胞移植后肝静脉阻塞症;陈洁等;《中华内科杂志》;20070228;第46卷(第2期);140-142 *

Also Published As

Publication number Publication date
CN103402527A (zh) 2013-11-20
EP2667878A1 (en) 2013-12-04
US20170042940A1 (en) 2017-02-16
JP2014508138A (ja) 2014-04-03
ES2573522T3 (es) 2016-06-08
CA2825252C (en) 2018-10-16
SG192124A1 (en) 2013-08-30
JP6012629B2 (ja) 2016-10-25
CA2825252A1 (en) 2012-08-02
DK2667878T3 (en) 2016-06-27
US20170354723A1 (en) 2017-12-14
US20130302291A1 (en) 2013-11-14
US10478459B2 (en) 2019-11-19
EP2667878B1 (en) 2016-03-30
US10039789B2 (en) 2018-08-07
IL227529A0 (en) 2013-09-30
WO2012101181A1 (en) 2012-08-02
PL2667878T3 (pl) 2016-10-31
PT2667878E (pt) 2016-06-03

Similar Documents

Publication Publication Date Title
CN103402527B (zh) 用于细胞移植的组合物和方法
JP6034406B2 (ja) 細胞移植のための組成物および方法
CA2733985C (en) Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
KR102357077B1 (ko) 분리된 신장 세포 및 이의 용도
ES2600321T3 (es) Medios para la regeneración del hígado
JP2019122381A (ja) 単離腎細胞を含有するオルガノイド及びその使用
JP2022532926A (ja) 幹細胞／前駆体の固形器官へのパッチ移植
BR112017008251B1 (pt) Usos de um tecido de um porco transgênico que compreende um gene a(1,3) galactosiltransferase, cmah e ß4galnt2 interrompido e de um produto relacionado com a pele, e, métodos para preparação de um material de transplante para xenoenxerto, para produção de um composto de interesse e para produzir um reagente de cultura de células
US20200216816A1 (en) Immunoprivileged bioactive renal cells for the treatment of kidney disease
US20190083542A1 (en) Adipose tissue-derived stem cells from transgenic porcine animals for veterinary use
TR201809635T4 (tr) Osteoblastik fonksiyonun arttırılmasına yönelik yöntemler.
BR112021011273A2 (pt) Composição celular que compreende células progenitoras do fígado que expressam hla-e
WO2022123958A1 (en) Pharmaceutical composition for use in prevention and treatment of liver fibrosis and/or liver cirrhosis, comprising adipose-derived regenerative cells (adrcs)
WO2019050546A2 (en) METHODS OF TREATMENT AND PREVENTION OF ACUTE HEALTH INSUFFICIENCY
WO2024152030A1 (en) Crossmatching for porcine xenotransplantation
Guerini et al. FTY720 ACTIVATION OF G PROTEIN-GATED POTASSIUM CHANNEL IKACh 1 AND 4 BUT NOT 1 AND 2 HETERODIMERS ARE RESPONSIBLE FOR THE CHRONOTROPIC EFFECT IN HEART, WHICH EXPLAINS LACK OF SIMILAR EFFECTS IN BRAIN.
Grappiolo et al. TNF-α, IL-10 AND TGF-β1 GENE POLYMORPHISMS IN RENAL TRANSPLANT OUTCOME IN A ROSARIO POPULATION, ARGENTINE.
Zhang et al. THE PROTECTION OF N-ACETYLEYSTEINE ON HEPATIC INJURY OF BRAIN-DEAD RATS.
Reckers et al. MEDIAL MENISCUS TRANSPLANTATION USING SYNTHETIC GLUE FOR FIXATION IN RABBITS1
Shi et al. THE PROTECTION EFFECTS OF GLYCINE PRETREATMENT ON BRAIN-DEAD DONOR LIVER.
BR122024023993A2 (pt) Método de produção de uma célula renal bioativa genomicamente modificada (brc), brc engenheirada e seu uso

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20131120

Assignee: Promise La Biosciences Co

Assignor: UNIVERSITE CATHOLIQUE DE LOUVAIN

Contract record no.: 2016990000248

Denomination of invention: Compositions and methods for cell transplantation

Granted publication date: 20160420

License type: Exclusive License

Record date: 20160621

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160420

Termination date: 20220125

CF01 Termination of patent right due to non-payment of annual fee